Edition:
United States

Advanced Search

Display
per page
  Report Title Date Provider Type Pgs Price

Coland Holdings Ltd: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.

This report is essential reading for any serious investor, providing comprehensive financial information on a company's perfo...

20 Aug 2016 Reuters Investment Profile 12 $20.00

Thomson Reuters Stock Report - Coland Holdings Ltd (4144-TW)

StockReports+ gathers Thomson Reuters independent research, ratings and market data into a single report that optimizes the i...

24 Aug 2016 Thomson Reuters Stock Report 11 $25.00

Wright Investors Service Comprehensive Report for Coland Holdings Limited

Quantitative analyses of financial statements (Income Statement, Balance Sheet and Sources of Capital), extensive ratio table...

30 Jul 2016 Wright Reports 60 $75.00

Thomson Reuters Stock Report - Coland Holdings Ltd (4144-TW)

StockReports+ gathers Thomson Reuters independent research, ratings and market data into a single report that optimizes the i...

10 May 2016 Thomson Reuters Stock Report 11 $25.00

Coland Pharmaceutical (4144 TT); Beneficiary of China’s Healthcare Reform

M&A and non-operating business used to fuel Coland’s growth. After the drug procurement bidding process, Coland’s core busine...

08 Dec 2015 MasterLink Securities Corporation 6 $58.00

Coland Pharmaceutical (4144 TT): China Commenced Centralized Drug Procurement Bidding

Our sales forecast for 2015 is NT$2.5bn, +15% YoY, with estimated EPS of NT$5.41, and NT$3.49 excluding gain on disposal. We ...

15 Jan 2015 MasterLink Securities Corporation 7 $69.00

F-康聯 (4144):中國藥品集中招標已陸續展開

元富預估2015年營收25億元,YOY+15%,EPS 5.41元,扣除處分利益EPS 為3.49元;2016年新產品在各省陸續出貨,預估營收32億元,YOY +25%,EPS 6.81元,扣除處分利益EPS 為4.89元,YOY +41%。我們分析...

13 Jan 2015 MasterLink Securities Corporation 6 $46.00

Coland Pharmaceutical (4144 TT): Drug Bidding Schedule in China Remains Uncertain

We forecast Coland’s FY14 sales of NT$2.1bn with EPS of NT$5.29, and number will be NT$2.92 after leaving out gains from disp...

08 Oct 2014 MasterLink Securities Corporation 6 $58.00

F-康聯 (4144):中國藥品招標時程難以掌握

康聯2014年營收21億元,EPS 5.29元,扣除處分利益EPS 為2.92元,給予20 X PE 合理價值為58.4元;康聯轉投資可貢獻NAV11.3元,綜合上述合理價值為70元。我們分析康聯近幾年營收成長主要來自併購,康聯本業則因營收佔比最大的...

01 Oct 2014 MasterLink Securities Corporation 5 $35.00

Coland Pharmaceutical (4144 TT): Ready to Bear Fruit

Coland’s FY13 sales soared 7.9% YoY to NT$1.86bn, with projected EPS of $5.02; FY14 sales are expected to rise 13.2% YoY to N...

04 Mar 2014 MasterLink Securities Corporation 7 $69.00